Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0406 • ACR Convergence 2023
Obesity Is a Risk Factor for Poor Response to Treatment in Early Rheumatoid Arthritis – a NORD-STAR Spin-Off Study
Violetta Dubovyk¹, Gerdur Maria Grondal², Bjorn Gudbjornsson³, Espen A Haavardsholm⁴, Marte Schrumpf Heiberg⁴, Merete Hetland⁵, Kim Hørslev-Petersen⁶, Meliha Kapetanovic⁷, Alf Kastbom⁸, John Lampa⁹, Kristina Lend¹⁰, Dan Nordstrom¹¹, Michael Nurmohamed¹², Milad Rizk¹³, Annika Söderbergh¹⁴, Till Uhlig¹⁵, Mikkel Østergaard¹⁶, Ronald van Vollenhoven¹², Anna Rudin¹⁷ and Cristina Maglio¹⁸, ¹University of Gothenburg, Gothenburg, Sweden, ²Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ³Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁶University of Southern Denmark, Odense, Denmark, ⁷Lund University and Skåne University Hospital, Lund, Sweden, ⁸Linköping University, Linköping, Sweden, ⁹Stockholm County, Hãsselby, Sweden, ¹⁰Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹³Västmanlands Hospital Västerås, Västerås, Sweden, ¹⁴Örebro University Hospital, Örebro, Sweden, ¹⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ¹⁷Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ¹⁸Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Several therapeutic options are currently available to treat rheumatoid arthritis (RA); however, the response to treatment is highly variable, and not all patients achieve…
Abstract Number: 0422 • ACR Convergence 2023
Electronic Health Record-Based Machine Learning Model for Predicting Disease Activity in Patients with Rheumatoid Arthritis
Zelin Yun¹, Chun Li² and Zhanguo Li², ¹Peking University People's Hospital, Beijing, China, ²Peking University People’s Hospital, Beijing, China
Background/Purpose: Rheumatoid arthritis (RA) is one of the most prevalent chronic inflammatory diseases in which synovitis gradually leads to polyarthritis and joint destruction. Poor response…
Abstract Number: 0439 • ACR Convergence 2023
Humoral Immune Response to 13 Valent-conjugate and 23-valent Polysaccharide Pneumococcal Vaccines in RA Patients Treated with Abatacept: Results of the Open Randomized Controlled Trial VACINA (Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients)
JACQUES MOREL¹, Olivier Brocq², Cécile Gaujoux Viala³, Arnaud Constantin⁴, Slim Lassoued⁵, Emanuelle Dernis⁶, Christophe Richez⁷, Cedric Lukas⁸, Claire Daien⁹ and Claire Duflos¹⁰, ¹Protocole thérapeutique immuno-rhumatologie, Montpellier, France, ²Hospital of Princesse Grâce de Monaco, Monaco, Monaco, ³IDESP Univ Montpellier, INSERM, Rheumatology, CHU Nîmes, Montpellier, France, ⁴Teaching hospital Purpan, and University of Paul Sabatier, Toulouse, France, ⁵Hospital of Jean-Rougié, Cahors, France, ⁶CH Le Mans, Le Mans, France, ⁷Université de Bordeaux, Bordeaux, France, ⁸CHU Montpellier, Montpellier, France, ⁹University Hospital, Montpellier, France, ¹⁰CHU and University of Montpellier, Montpellier, France
Background/Purpose: To prevent infections, EULAR recommends to vaccinate RA patients against streptococcal pneumoniae. PCV13 is a T- cell dependent vaccine whereas PPSV23 induces a T-independent…
Abstract Number: 0456 • ACR Convergence 2023
The “Topics” in the Electronic Health Record of Rheumatoid Arthritis Patients Before Initiating Targeted Therapies and Association with Future Treatment Course
Jason Tang¹, Dana Weisenfeld², Kumar Dahal², Linshanshan Wang³, Clara-Lea Bonzel³, Yumeko Kawano², Gregory McDermott², Tianxi Cai⁴ and Katherine Liao², ¹Harvard College, Belmont, MA, ²Brigham and Women's Hospital, Boston, MA, ³CELEHS Lab, Cambridge, MA, ⁴Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Strong clinical predictors for response to biologic and targeted synthetic disease modifying rheumatic drugs (b/tsDMARDs) in rheumatoid arthritis (RA) have yet to be identified.…
Abstract Number: 0735 • ACR Convergence 2023
Deep Immunophenotyping Reveals Circulating Activated Lymphocytes in Individuals at Risk for Rheumatoid Arthritis
Jun Inamo¹, Joshua Keegan², Alec Griffith², Tusharkanti Ghosh³, Alice Horisberger², Kaitlyn Howard², John Pulford², Ekaterina Murzin², Brandon Hancock², The Accelerating Medicines Partnership SLE/RA⁴, Marie Feser⁴, Jill Norri⁵, Anna Helena Jonsson⁶, Ye Cao⁷, William Apruzzese⁸, S. Louis Bridges⁹, Vivian Bykerk¹⁰, Susan Goodman⁹, Laura Donlin⁹, Gary S Firestein¹¹, Harris Perlman¹², Joan Bathon¹³, Laura Hughes¹⁴, Darren Tabechian¹⁵, Andrew Filer¹⁶, Costantino Pitzalis¹⁷, Jennifer Anolik¹⁵, Larry Moreland¹⁸, Joel Guthridge¹⁹, Judith James¹⁹, Michael Brenner², Soumya Raychaudhuri⁶, Jeffrey Sparks²⁰, Jennifer Seifert²¹, Michael Holer⁴, Kevin Deane⁴, James Lederer², Deepak Rao⁶ and Fan Zhang²², ¹University of Colorado School of Medicine, Aurora, CO, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵Colorado School of Public Health, Denver, CO, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Department of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Department of Medicine, University of California San Diego, La Jolla, CA, ¹²Northwestern University, Chicago, IL, ¹³Columbia University, New York, NY, ¹⁴University of Alabama at Birmingham Medicine, Birmingham, AL, ¹⁵University of Rochester Medical Center, Rochester, NY, ¹⁶University of Birmingham, Birmingham, United Kingdom, ¹⁷Queen Mary University of London, London, United Kingdom, ¹⁸University of Colorado, Denver, CO, ¹⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ²¹The Accelerating Medicines Partnership RA/SLE Network, ²²University of Colorado, Aurora, CO

Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with currently no effective prevention strategies. Single-cell technologies have been used to investigate established RA heterogeneity…
Abstract Number: 0798 • ACR Convergence 2023
A Novel 3D Model of Rheumatoid Arthritis Synovial Tissue Incorporating Fibroblasts, Endothelial Cells and Macrophages
Eva Philippon¹, Lisanne van Rooijen¹, Jan Piet van Hamburg¹, Fatemeh Khodadust¹, Conny Van der Laken² and Sander Tas³, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Amsterdam UMC - location VUMC, Amsterdam, Netherlands, ³Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder associated with chronic and destructive inflammation of the joints. The hallmarks of RA are…
Abstract Number: 0967 • ACR Convergence 2023
Overall Survival in Patients with versus Without Rheumatoid Arthritis Initiating Immune Checkpoint Inhibitors for Metastatic Non Small Cell Lung Cancer
Deanna Jannat-Khah¹, Jeffrey R Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne Bass⁵, ¹Hospital For Special Surgery, New York, NY, ²Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) increase one-year survival in metastatic non-small cell lung cancer (mNSCLC) from 49% to 69% with chemotherapy-based regimens. Patients with rheumatoid…
Abstract Number: 0996 • ACR Convergence 2023
Will Patients Engage with Digital Technologies as Part of Routine Healthcare?
Jeffrey R Curtis¹, Sandeep Sodhi², Yuji Su³, Scott Laster⁴, Fenglong Xie², Ye Liu⁵ and Corey Patrick⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ²Illumination Health, Hoover, AL, ³University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ⁴Micare, Memphis, TN, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM) are new care delivery options by which patients can provide data to their provider via…
Abstract Number: 1077 • ACR Convergence 2023
Anti-drug Antibodies Formation During Tapering and Stopping of Methotrexate in Rheumatoid Arthritis Patients with Longstanding Use of Adalimumab
Zohra Layegh¹, Pascal de Jong¹, Sadaf Atiqi², Floris loeff³, lisanne Dijk³, Gaelle vaz³, radboud J.e.m. Dolhain⁴, Theo Rispens³ and Gertjan Wolbink⁵, ¹Erasmus medical center, Rotterdam, Netherlands, ²Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Dr. Jan van Breemenstraat 2, 1056 AB, Amsterdam, Netherlands, ³Sanquin Diagnostic Service, Biologics Laboratory, Amsterdam, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: Due to better effectiveness and longer drug survival, a TNF inhibitor (TNFi) should preferably be combined with methotrexate (MTX). MTX has been found to…
Abstract Number: 1273 • ACR Convergence 2023
Long-term Follow-up of Treated-to-target RA and UA: Results of the BeSt and IMPROVED Studies
Sascha Heckert¹, Johanna Maria Maassen¹, Isabell Nevins², F. Fodili³, Margreet Steup-Beekman⁴, Thomas Huizinga¹, Sytske Anne Bergstra¹ and CF Allaart¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Amsterdam, Netherlands, ³Stichting ReumaZorg ZWN, Roosendaal, Netherlands, ⁴Leiden University Medical Center, Den Haag, Netherlands
Background/Purpose: In 2 trials with an original follow-up of 5-10 years, patients with early arthritis were treated to target, resulting in low disease activity or…
Abstract Number: 1289 • ACR Convergence 2023
Increases in Serum Levels of Tartrate-Resistant Acid Phosphatase 5b Reflected Radiographic Progression of Joint Damage in Treated Rheumatoid Arthritis
Takayoshi Owada¹, Takayuki Kobayashi¹, Ayae Tanaka², Kei Ikeda², Hirokuni Hirata¹, Masafumi Arima³, Kazuhiro Kurasawa² and Yasutsugu Fukushima¹, ¹Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan, ²Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Japan, ³Dokkyo Medical University, Koshigaya, Japan
Background/Purpose: Rheumatoid Arthritis (RA) is one of inflammatory arthritis, and this autoimmune-mediated polyarthritis results in structural joint destruction. Articular bone erosion leading to joint destruction in RA…
Abstract Number: 1305 • ACR Convergence 2023
Variations in Macrophage Cholesterol Loading over Time Are Linked to Dynamic Changes in Coronary Atherosclerotic Plaque in Rheumatoid Arthritis
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo⁴, Elizabeth Hernandez³, Maria Pia Adorni⁵, Francesca Zimetti², Matthew Budoff¹ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Department of Food and Drug, Parma, Italy, ³The Lundquist Institute, Torrance, CA, ⁴University of Parma, Parma, Italy, ⁵Department of Medicine and Surgery, Unit of Neuroscience, University of Parma, Parma, Italy
Background/Purpose: The ability of serum to deliver cholesterol to cells is known as cholesterol loading capacity (CLC) and associates with foam cell formation. In rheumatoid…
Abstract Number: 1322 • ACR Convergence 2023
Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
Christoph Burkart, Clara Polizzi, Lisa Eide, Max Pastenes, David Siefker and Leslie Nangle, aTyr Pharma, San Diego, CA
Background/Purpose: Efzofitimod, a novel immunomodulator, has shown clinical proof-of-concept in a Phase 1b/2a clinical trial in patients with pulmonary sarcoidosis and is currently enrolling a…
Abstract Number: 1338 • ACR Convergence 2023
The Advantage of Tight Control and Treat-to-Target in New-onset Rheumatoid Arthritis Patients in Daily Rheumatology Practice: Results from a Contemporary University Clinic Inception Cohort
Katarina Friberger Pajalic¹, Jon Thorkel Einarsson¹, Caroline Bengtsson², Ellen Landgren³, Elisabeth Mogard⁴, Carmen Roseman⁵, Johan Karlsson Wallman⁴, Elisabet Lindqvist⁴, Tor Olofsson⁴ and Meliha Kapetanovic⁴, ¹Lund University, Institution for clinical sciences, section for rheumatology Lund and Lund University Hospital, Lund, Sweden, ²Lund University Hospital, section for rheumatology, Lund, Sweden, ³Lund University, Institution for clinical sciences, section for rheumatology Lund and Skåne University Hospital, Lund, Sweden, ⁴Lund University and Skåne University Hospital, Lund, Sweden, ⁵Lund University, Institution for clinical sciences, section for rheumatology Lund and Lund University Hospital, Lund, Sweden
Background/Purpose: Since 2018, all patients with new-onset rheumatoid arthritis (RA) at the Department of Rheumatology, Skåne University Hospital, Lund, Sweden, are invited to participate in…
Abstract Number: 1627 • ACR Convergence 2023
Methotrexate Use Associates with Ischemic Cardiovascular Risk Reduction in Males but Not Females with Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth², Piet Van Riel³, Elena Myasoedova⁴, Miguel A Gonzalez-Gay⁵, Alfonso Corrales⁶, Solbritt Rantapää-Dahlqvist⁷, Petros Sfikakis⁸, Patrick Dessein⁹, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawi¹⁰, Virginia Pascual Ramos¹¹, Irazú Contreras Yañez¹², Iris Colunga¹³, Dionicio A. Galarza-Delgado¹³, José Ramón Azpiri-López¹³, Silvia Rolefstad¹⁴, Anne Grete Semb¹⁵, Durga P Misra¹⁶, GEORGE KITAS¹⁷ and Ellen Margrethe Hauge¹⁸, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Torrance, CA, ³Radboud University Medical Center, Drunen, Netherlands, ⁴Mayo Clinic, Rochester, MN, ⁵IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁶Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁷Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁸National Kapodistrian University of Athens Medical School, Athens, Greece, ⁹University of Witwatersrand, Johannesburg, South Africa, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹³Hospital Universitario UANL, Monterrey, Mexico, ¹⁴Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, ¹⁵Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁷The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ¹⁸Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) experience higher cardiovascular risk compared to non-inflammatory disease controls. Methotrexate (MTX) may decrease cardiovascular risk in patients with RA.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].